In Study, Sorafenib Plus Everolimus for Osteosarcoma Fails to Reach Primary Endpoint
the Cancer Therapy Advisor take:
According to a new study published in the journal The Lancet Oncology, the combination of sorafenib and everolimus failed to meet the prespecified 6 month progression-free survival target for the treatment of patients with relapsed or unresectable osteosarcoma.
For this non-randomized phase 2 study, researchers enrolled 38 adults between 2011 and 2013 with relapsed or unresectable osteosarcoma who progressed after standard chemotherapy. Standard chemotherapy include cisplatin, doxorubicin, methotrexate, with or without ifosfamide. Patients received sorafenib 800mg/day orally and everolimus 5mg orally once daily until disease progression or unacceptable toxicity.
Results showed that a 6 months, 45% of those enrolled (95% CI: 28 - 61) were progression-free. In regard to safety, 66% of patients experienced adverse event-related dose reductions, short therapy interruptions, or both, and 5% of patients discontinued treatment.
The most frequent grade 3 or 4 adverse events were anemia, diarrhea, fatigue, hand and foot syndrome, hypophosphatemia, lymphopenia, oral mucositis, and thrombocytopenia. One patient experienced a grade pneumothorax and again when that patient's disease progressed.
Despite the combination's demonstrated efficacy, the study did not reach its primary endpoint of 6 month progression-free survival of 50% or higher.
Sorafenib and everolimus failed to meet the prespecified 6 month progression-free survival target
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer